DataM Intelligence | competitive Intelligence CIDP treatment evolves with novel approvals like Vyvgart Hytrulo and HYQVIA, offering patient ...

慢性炎症性脱髓鞘性多发性神经病（CIDP）长期以来被定义为一种纯粹累及周围神经系统的自身免疫性疾病，典型表现为四肢对称性无力和感觉障碍。然而临床观察中，患者常抱怨"脑子转得慢"或"记不住事"，这些现象用传统病理机制难以解释。更令人困惑的是，作为神经轴索损伤标志物的血清神经丝轻链（sNfL）在CIDP患者中异常升高——这本是阿尔茨海默病、多发性硬化等中枢神经系统疾病的特征性改变。这些矛盾现象引发了一 ...

Retinitis Pigmentosa therapies evolve beyond gene-specific fixes with gene-agnostic, intravitreal, and optogenetic advances ...

Intellia’s stock fell 23% after one patient in its Phase III MAGNITUDE trial developed severe liver toxicity that later ...

Shares of Intellia Therapeutics NTLA were down 22.9% yesterday after it announced an update from the ongoing phase III study, ...

Shares of Intellia Therapeutics fell after the company reported a grade 4 adverse event in a study of nex-z, its treatment for hereditary ATTR amyloidosis with polyneuropathy. The stock was down 24% ...

The clinical-stage immunology company reported a net loss of $0.64 per share for the quarter, lower than an estimated loss of ...

Intellia Therapeutics’ stock may have taken a hit in the wake of details of a grade 4 adverse event in a phase 3 trial, but ...

Research Question: What are the root causes of suboptimal multidisciplinary care that contribute to delayed diagnosis and comprehensive management of cardiomyopathy (CM) and polyneuropathy (PN) ...

Guillain-Barré Syndrome (GBS) stands as one of the most common subtypes of acute polyneuropathy, affecting two out of 100,000 individuals annually. Some estimates indicate a greater occurrence of the ...

Critical illness polyneuropathy (CIP) and critical illness myopathy (CIM) are major complications that occur in severely ill patients who require intensive care treatment. CIP and CIM affect the ...

Copyright: © 2024 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.